Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Mindray, officially known as Shenzhen Mindray Bio-Medical Electronics Co., Ltd., is a leading Chinese company specialising in medical, precision, and optical instruments, including watches and clocks. Headquartered in Shenzhen, China, the firm has established a significant presence across Asia, North America, and Europe, serving a global healthcare market. Founded in 1991, Mindray has grown to become a prominent player in medical imaging, patient monitoring, and laboratory diagnostics, recognised for its innovative technology and reliable products.
The company's core offerings include advanced medical devices such as ultrasound systems, patient monitors, and in-vitro diagnostic instruments, distinguished by their high quality and affordability. With a strong market position, Mindray continues to expand its footprint through technological innovation and strategic partnerships, maintaining its reputation as a trusted provider in the medical equipment industry.
0 vs industry average
Mindray’s score of 32 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing is among the most carbon-intensive industries
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
Mindray, a medical, precision and optical instruments, watches and clocks company headquartered in CN, reported its 2024 carbon emissions as approximately 5,327,980 kg CO2e for Scope 1, 68,619,750 kg CO2e for Scope 2, and 94,210,380 kg CO2e for Scope 3.
In 2023, the company's Scope 1 emissions were about 7,207,560 kg CO2e and Scope 2 emissions were approximately 67,978,550 kg CO2e. For 2022, Mindray's Scope 1 emissions were roughly 6,806,130 kg CO2e and Scope 2 emissions were about 64,620,020 kg CO2e. In 2021, combined Scope 1 and Scope 2 emissions were approximately 61,047,060 kg CO2e, and in 2020, they were about 55,496,770 kg CO2e. Furthermore, in 2019, combined Scope 1 and Scope 2 emissions stood at roughly 50,093,770 kg CO2e.
Mindray has committed to a near-term intensity reduction target for its GHG emissions. The company aims to reduce its Scope 1 and Scope 2 GHG intensity by 25% by 2030, using a 2021 baseline. This emissions data is cascaded from the parent company, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more